COMMUNIQUÉS West-GlobeNewswire

-
Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy
03/12/2018 -
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
03/12/2018 -
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
03/12/2018 -
Golden Leaf Holdings favorably restructures deal terms with Tahoe Hydroponics
03/12/2018 -
Eve & Co Provides Update on Phase 2 Expansion
03/12/2018 -
TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
03/12/2018 -
Press release: Terveystalo renews its management structure - decision making and service development closer to the customer
03/12/2018 -
Enochian Biosciences to Present at Biotech Showcase 2019
03/12/2018 -
Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer
03/12/2018 -
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
03/12/2018 -
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
03/12/2018 -
Novo Nordisk A/S - Share repurchase programme
03/12/2018 -
XBiotech Announces Successful Completion of GMP Audit
03/12/2018 -
Data Presented at AACR Special Conference on PI3K/mTOR Signaling Demonstrates Potential of eFFECTOR’s eIF4E Inhibitors in Cancer
03/12/2018 -
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2019 After Market Close on December 10, 2018
03/12/2018 -
Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
03/12/2018 -
Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita®
03/12/2018 -
Selecta Biosciences Announces New Employment Inducement Grants
03/12/2018 -
GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
03/12/2018
Pages